Merck clears PFS endpoint in confirmatory trial for Keytruda in classical Hodgkin lymphoma
Classical Hodgkin lymphoma was the first blood cancer that Merck’s Keytruda was approved to treat. Three years after that OK arrived — kicking off a spate of new indications for the star PD-1 inhibitor — the company finally has some solid evidence of its effect.
Building on the overall response rates that convinced FDA regulars to hand down an accelerated approval in March 2017, Merck said Keytruda hit a co-primary endpoint on progression-free survival in the Phase III confirmatory trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.